
Tirzepatide is a synthetic peptide investigated in experimental and clinical research as a dual incretin receptor agonist, targeting both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. This dual agonist design enables researchers to study the coordinated activation of two key incretin pathways involved in metabolic regulation, endocrine signaling, and nutrient utilization.


Videos de creadores independientes en YouTube. BioVantix no los produce ni los respalda, y no son instrucciones de uso. Se cargan desde YouTube solo al reproducirlos.